First Eagle Investment Management LLC Cuts Stake in Amedisys, Inc. (NASDAQ:AMED)

First Eagle Investment Management LLC decreased its position in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 64.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 25,300 shares of the health services provider's stock after selling 46,876 shares during the period. First Eagle Investment Management LLC owned about 0.08% of Amedisys worth $2,405,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Amedisys by 0.4% in the third quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider's stock worth $302,724,000 after purchasing an additional 12,137 shares in the last quarter. Alpine Associates Management Inc. boosted its stake in shares of Amedisys by 23.0% during the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider's stock worth $120,830,000 after buying an additional 237,600 shares during the last quarter. Pentwater Capital Management LP grew its holdings in shares of Amedisys by 239.5% in the 3rd quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider's stock valued at $106,850,000 after acquiring an additional 807,000 shares in the last quarter. Westchester Capital Management LLC increased its position in shares of Amedisys by 269.7% in the third quarter. Westchester Capital Management LLC now owns 850,386 shares of the health services provider's stock valued at $79,426,000 after acquiring an additional 620,386 shares during the last quarter. Finally, Segantii Capital Management Ltd bought a new stake in Amedisys during the fourth quarter worth about $32,776,000. Institutional investors and hedge funds own 94.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on AMED shares. StockNews.com raised Amedisys from a "hold" rating to a "buy" rating in a research report on Saturday, May 4th. Royal Bank of Canada upped their price target on shares of Amedisys from $97.00 to $100.00 and gave the stock an "outperform" rating in a research report on Monday, March 25th. Raymond James reiterated a "market perform" rating on shares of Amedisys in a research note on Tuesday, March 26th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $101.00 price objective on shares of Amedisys in a research note on Thursday, April 25th. Seven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Amedisys has an average rating of "Hold" and a consensus price target of $100.80.

Amedisys Stock Performance

Shares of NASDAQ AMED traded down $0.52 during trading hours on Friday, reaching $94.43. 196,779 shares of the stock were exchanged, compared to its average volume of 237,447. The stock's fifty day simple moving average is $92.61 and its 200 day simple moving average is $93.50. The firm has a market capitalization of $3.09 billion, a price-to-earnings ratio of -147.55, a P/E/G ratio of 3.53 and a beta of 0.84. Amedisys, Inc. has a 52 week low of $74.61 and a 52 week high of $96.44. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.09 and a current ratio of 1.09.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Amedisys had a negative net margin of 0.91% and a positive return on equity of 12.85%. The company had revenue of $571.41 million during the quarter, compared to analysts' expectations of $565.38 million. During the same quarter in the previous year, the business posted $1.00 earnings per share. Amedisys's quarterly revenue was up 2.7% on a year-over-year basis. Sell-side analysts predict that Amedisys, Inc. will post 4.57 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.